Gyrodyne, LLC: management transactions · United States · SEC (Form 4)

About Gyrodyne, LLC

Gyrodyne, LLC is a U.S.-listed real estate company trading on NASDAQ under the ticker GYRO. For French-speaking investors, the key point is that Gyrodyne is not a broad-based REIT with a large national portfolio; it is a concentrated, asset-driven real estate platform focused on extracting value from a small number of properties. The company is organized as a New York limited liability company and is headquartered in Smithtown, New York. Its operating history on Long Island spans more than 70 years, giving it a long local footprint and deep familiarity with its core submarkets. ([gyrodyne.com](https://gyrodyne.com/?utm_source=openai)) Gyrodyne’s core business today is the ownership, operation, and management of a portfolio of medical office and industrial real estate, combined with the pursuit of entitlements and development rights tied to those assets. The company states that its properties are located in Suffolk County, at Flowerfield, and in Westchester County, at Cortlandt Manor, both in New York State. It reports that it owns and manages more than 161,000 square feet of rentable space across nine buildings, indicating a relatively small but focused operating base. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1589061/000143774926010078/gyrllc20251231_10k.htm?utm_source=openai)) Strategically, Gyrodyne is positioned in a niche healthcare real estate segment that has historically benefited from durable demand for medical office space and related uses. The company notes that it was previously a publicly traded REIT and later sharpened its focus on healthcare-related real estate. Its competitive edge is less about scale and more about asset quality, site location, and optionality: value creation can come from entitlement work, redevelopment potential, and eventual monetization of land and buildings. This makes the name more of a special situation than a conventional property operator. ([gyrodyne.com](https://gyrodyne.com/company_about.php?utm_source=openai)) Recent developments reinforce that special-situation profile. In its 2025 annual report, Gyrodyne states that its financial statements are prepared on a liquidation basis, which signals a strategy centered on orderly realization of value rather than long-term portfolio expansion. The company disclosed a net realizable value of $53.99 million for remaining real estate at December 31, 2025, with the year-over-year increase driven mainly by entitlement status and market conditions. In August 2025, Gyrodyne also highlighted development-related progress and potential economic output from the campus, while SEC Form 4 filings in 2025 indicate ongoing insider transaction activity that market participants may monitor closely. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001589061/000143774926010078/gyrllc20251231_10k.htm?utm_source=openai)) In short, Gyrodyne is a small-cap U.S. real estate company listed on NASDAQ in the United States, best understood as a value-realization story tied to New York land, medical office assets, and the success of entitlement and redevelopment initiatives.